Abstract
Background: This study is aimed to different doses of Dexmedetomidine as an adjuvant to Intrathecal hyperbaric bupivacaine in lower limb orthopaedic surgeries
 Methods: A prospective randomized double blind study was conducted with 90 consenting patients of ASA grade I and II, scheduled for lower limb Orthopaedic surgeries. Using the lottery method, the patients were randomly allotted into 3 groups, 30 patients in each group. Group I , Group II & Group III. 
 Results: Post-operative VAS and total analgesic requirement in 24 hours were minimal in group C as compare to B group. All the patients achieved Bromage scale 3 motor block and there was dose dependent prolongation of motor block in B and C groups.
 Conclusion: Supplementation of spinal Bupivacaine with Dexmedetomidine significantly prolonged both sensory and motor block compared with intrathecal Bupivacaine alone.
 Keywords: Bupivacaine, Dexmedetomidine, Motor block.
Highlights
Pain is an unpleasant feeling often caused by intense or damaging stimuli
Background: This study is aimed to different doses of Dexmedetomidine as an adjuvant to Intrathecal hyperbaric bupivacaine in lower limb orthopaedic surgeries Methods: A prospective randomized double blind study was conducted with 90 consenting patients of ASA grade I and II, scheduled for lower limb Orthopaedic surgeries
Post-operative VAS and total analgesic requirement in 24 hours were minimal in group C as compare to B group
Summary
Pain is an unpleasant feeling often caused by intense or damaging stimuli. It has been defined by the International Association for the Study of Pain (IASP) as “An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage”. 1. Dexmedetomidine is highly selective α2 adrenergic agonist. Dexmedetomidine has been used as intrathecally as an adjuvant and no neurological side-effect is reported in humans. It provides stable hemodynamic condition, good quality of intra-operative and prolonged postoperative analgesia with minimal side effects. Intrathecal α2 receptor agonists are found to have antinociceptive action for both somatic and visceral pain. Intrathecal α2 receptor agonists are found to have antinociceptive action for both somatic and visceral pain. 2-4
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Medical and Biomedical Studies
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
